Compare TG Therapeutics Inc (TGTX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vertiv Holdings Co — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Vertiv Holdings Co trades at $304.63 (market cap $112.03B). The key difference: Vertiv Holdings Co is far larger — about 13.6× TG Therapeutics Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VRT | |
|---|---|---|
Market Cap | $8.26B | $112.03B |
Sector | Health | Technology |
52-Week High | $59.06 | $376.23 |
52-Week Low | $26.39 | $121.82 |
Enterprise Value | $8.50B | $112.80B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Vertiv (VRT) trades at $291.67, up 0.73% today, with a bearish technical signal but strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected on July 29, 2026. Revenue and net income are projected to grow in 2026, supported by robust demand for AI data center infrastructure, including recent expansions in cooling solutions manufacturing.
The outlook is positive due to AI-driven growth and a $15 billion order backlog, though high valuation multiples and technical weakness pose risks. Analyst consensus is strongly bullish with a $402.92 price target, but investors should monitor execution on growth targets and competitive pressures in the data center equipment market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
